Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development
STAT
MARCH 8, 2024
Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug.
Let's personalize your content